O2h Ventures is a Cambridge-based venture capital firm founded in 2018 that operates as a specialized fund. See sector focus, stage focus and contact routes.
O2h Ventures is a Cambridge-based venture capital firm founded in 2018 that operates as a specialized fund manager within the UK’s biotech ecosystem, focusing on early-stage human health investments [1][2][12]. The firm’s investment thesis targets pre-seed and seed-stage biotech therapeutics and companies at the intersection of biotechnology with artificial intelligence or machine learning, primarily in the United Kingdom with plug-in capabilities in India and a bridge to the USA [2][3][13]. O2h Ventures invests through HMRC-approved Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS) funds, with minimum investor commitments of £25,000 for EIS and £10,000 for SEIS, though specific per-company check sizes are not publicly disclosed [3][6][7]. The firm has deployed over $10 million across 35+ early-stage biotech companies addressing unmet medical needs in areas including cancer, depression, eye and ear diseases, psoriasis, pulmonary fibrosis, anti-ageing, and infectious diseases [6]. While the search results do not list specific named portfolio companies, the firm emphasizes novel drug discovery, enabling service tools, and AI/ML technologies as core inves
Every field above is read from the StartupFundraising firm directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Cambridge when building a target list.
Investors like O2h Ventures · Full investor directory · Investor access · Company funding database